Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Erlotinib in patients with advanced lung squamous cell carcinoma.

Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF, Chiu CH, Lee YC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):203-8. doi: 10.1007/s00280-012-1997-5. Epub 2012 Oct 10.

PMID:
23053274
2.

Retrospective study of erlotinib in patients with advanced squamous lung cancer.

Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC.

Lung Cancer. 2012 Jul;77(1):128-33. doi: 10.1016/j.lungcan.2012.02.012. Epub 2012 Mar 13.

PMID:
22420950
3.

Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.

Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C.

Respirology. 2009 Jul;14(5):709-15. doi: 10.1111/j.1440-1843.2009.01564.x.

PMID:
19659649
4.

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.

Cancer Chemother Pharmacol. 2012 May;69(5):1241-6. doi: 10.1007/s00280-012-1831-0. Epub 2012 Jan 26.

PMID:
22278730
5.

Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.

Hata A, Katakami N, Kunimasa K, Yoshioka H, Fujita S, Kaji R, Tachikawa R, Tomii K, Imai Y, Iwasaku M, Ishida T.

Jpn J Clin Oncol. 2011 Dec;41(12):1366-72. doi: 10.1093/jjco/hyr159. Epub 2011 Nov 3.

PMID:
22058419
6.

Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.

Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH.

Korean J Intern Med. 2010 Sep;25(3):294-300. doi: 10.3904/kjim.2010.25.3.294. Epub 2010 Aug 31.

7.

[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].

Shi C, Han B, Gu A, Xiong L, Shen J.

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):529-33. doi: 10.3779/j.issn.1009-3419.2011.06.09. Chinese.

8.

Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.

Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C.

Oncology. 2010;78(3-4):249-58. doi: 10.1159/000315731. Epub 2010 Jun 4.

PMID:
20523085
9.

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.

J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16.

PMID:
21576636
10.

Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).

Van Meerbeeck J, Galdermans D, Bustin F, De Vos L, Lechat I, Abraham I.

Eur J Cancer Care (Engl). 2014 May;23(3):370-9. doi: 10.1111/ecc.12146. Epub 2013 Oct 24.

PMID:
24152297
11.

Erlotinib in the treatment of advanced squamous cell NSCLC.

Fiala O, Pesek M, Finek J, Krejci J, Havel L, Hrnciarik M, Salajka F, Bortlicek Z, Benesova L, Minarik M.

Neoplasma. 2013;60(6):676-82. doi: 10.4149/neo_2013_086.

PMID:
23906302
12.

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.

Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130.

13.

Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.

Sheikh N, Chambers CR.

J Oncol Pharm Pract. 2013 Sep;19(3):228-36. doi: 10.1177/1078155212464087. Epub 2012 Nov 22.

PMID:
23175450
14.

Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.

Ironside JA, English JF, Kerr GR, Price A, Little FA, Erridge SC, Mackean MJ.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):550-3. doi: 10.1016/j.clon.2010.05.013. Epub 2010 Jun 2.

PMID:
20627674
15.

Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.

Xu XH, Su J, Fu XY, Xue F, Huang Q, Li DJ, Lu MQ.

Cancer Chemother Pharmacol. 2011 Feb;67(2):475-9. doi: 10.1007/s00280-010-1450-6. Epub 2010 Sep 16.

PMID:
20844881
16.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
17.

Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.

Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, Aziz F, Wang D, Zhang T.

Anticancer Drugs. 2011 Oct;22(9):842-52. doi: 10.1097/CAD.0b013e328349c303. Review.

PMID:
21808188
18.

Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.

Matsuura S, Inui N, Ozawa Y, Nakamura Y, Toyoshima M, Yasuda K, Yamada T, Shirai T, Suganuma H, Yokomura K, Suda T, Chida K.

Jpn J Clin Oncol. 2011 Aug;41(8):959-63. doi: 10.1093/jjco/hyr079. Epub 2011 Jun 28.

PMID:
21715361
19.

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.

Grossi F, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12. doi: 10.1007/s00280-012-1848-4. Epub 2012 Feb 21.

PMID:
22349923
20.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group.

J Clin Oncol. 2005 Sep 1;23(25):5892-9. Epub 2005 Jul 25.

PMID:
16043829

Supplemental Content

Support Center